KBC Group’s LENZ Therapeutics LENZ Stock Holding History

KBC Group’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$827K	Buy	+90,425	New	+$1.27M	﹤0.01%	738

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

KBC Group's LENZ Position: Q1 2026 in Review

KBC Group opened a new position in LENZ Therapeutics (LENZ) in Q1 2026: 90,425 shares worth $827K. The stake represents ﹤0.01% of the portfolio and ranks #738 among its holdings.

145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

KBC Group held 90,425 shares of LENZ Therapeutics worth $827K as of Q1 2026.
LENZ Therapeutics was a new KBC Group position in Q1 2026.
LENZ Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #738 holding.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.